Fluoroquinolones for respiratory infections: Too valuable to overuse

Chest

Volumn 120, Issue 6, 2001, Pages 1771-1775

  Williams Jr , James H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; AZITHROMYCIN; BETA LACTAM; BETA LACTAMASE INHIBITOR; CEFACLOR; CEFOTAXIME; CEFPROZIL; CEFRADINE; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; LIDAPRIM; MACROLIDE; MOXIFLOXACIN; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULBACTAM; TAZOBACTAM; TETRACYCLINE; TROVAFLOXACIN;

BACTERIUM ISOLATE; CHRONIC BRONCHITIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; EMPYEMA; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SPUTUM CULTURE; TREATMENT OUTCOME;

EID: 0035684095     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.120.6.1771     Document Type: Editorial

References (33)

1. Strategies for early discharge of the hospitalized patient with community-acquired pneumonia
2. Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin
3. Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: The relationship with in-vitro activity
4. High-dose intravenous fluoroquinolones in the treatment of severe infections
5. Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis
6. Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: Ciprofloxacin 750 mg b.i.d. versus clarithromycin 500 mg b.i.d.
7. Community-acquired pneumonia in adults: Guidelines for management; the Infectious Diseases Society of America
8. Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis
9. Penetration of intravenous and oral ciprofloxacin into sterile and empyemic human pleural fluid
10. Managing the nonsurgical candidate with an empyema related to community-acquired lobar pneumonia
11. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society; The Canadian Community-Acquired Pneumonia Working Group
12. Practice guidelines for the management of community-acquired pneumonia in adults: Infectious Diseases Society of America
13. Guidelines for community-acquired pneumonia: A tale of 2 countries
14. Nonvalue of the initial microbiological studies in the management of nonsevere community-acquired pneumonia
15. Antibiotic therapy of exacerbations of chronic bronchitis
16. Multiple antibiotic resistance in Stenotrophomonas maltophilia: Involvement of a multidrug efflux system
17. New uses for new and old quinolones and the challenge of resistance
18. Outbreaks of Staphylococcus aureus infections during treatment of late onset pneumonia with ciprofloxacin in a prospective, randomized study
19. Antibiotic susceptibility among aerobic Gram-negative bacilli in intensive care units in 5 European countries: French and Portuguese ICU Study Groups
20. Fluoroquinolone-resistant Haemophilus influenzae: Frequency of occurrence and analysis of confirmed strains in the SENTRY antimicrobial surveillance program (North and Latin America)
21. In-vitro and in-vivo activity of trovafloxacin against Streptococcus pneumoniae
22. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada: Canadian bacterial surveillance network
23. Increase in quinolone resistance in a Haemophilus influenzae strain isolated from a patient with recurrent respiratory infections treated with ofloxacin
24. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients
25. Molecular mechanisms of resistance in Pseudomonas aeruginosa to fluoroquinolones
26. Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia
27. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: A prospective, randomized, multicenter trial
28. Antibiotics in acute bronchitis: A meta-analysis
29. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis
30. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against 4151 Gram-negative and Gram-positive organisms
31. Levofloxacin, a second-generation fluoroquinolone
32. Bactericidal activity of levofloxacin and ciprofloxacin on clinical isolates of different phenotypes of Pseudomonas aeruginosa
33. Comparative in-vitro activity of levofloxacin against isolates of bacteria from adult patients with community-acquired lower respiratory tract infections